Abstract 548P
Background
Lung cancer is the malignant tumor with the highest incidence rate and mortality in the world. The main types of lung cancer are nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With targeted therapy and immunotherapy emerging, treating NSCLC has made a great progress. However, the molecular mechanisms underlying progression of NSCLC remain elusive.
Methods
Completing gain- and loss-of-function experiments to view whether B-Myb regulates the function of lung cancer cells by targeting IGFBP3 in lung cancer cell lines H1299 and A549, respectively. Mechanistically, Using a stable strain of B-Myb lung cancer to build the animal model and collecting mouse blood to lymphocyte subgroup analysis by flow cytometry. Analyzing metabolic products of lung cancer by metabolomics.
Results
B-Myb increased in lung cancer tissues and cells notably, its expression interrelated with clinical stage and poor prognosis of patients with NSCLC. B-Myb may affect the proliferation, invasion, and migration of NSCLC by regulating IGFBP3. Importantly, overexpressing of B-Myb in NSCLC affects the expression of immune checkpoint PD-1/PD-L1 and lung cancer cell metabolism.
Conclusions
Our findings reveal that B-Myb may interact with IGFBP3 to promote the occurrence and development of NSCLC and affect immune checkpoints PD-1/PD-L1 expressing. B-Myb may become a potential new target for the diagnosis and treatment of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chongqing Municipal Education Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract